"Delivery of this report will take 1-3 days after purchase."
Global Genetic disorders Partnering 2010-2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access t- the genetic disorders partnering deals and agreements entered int- by the worlds leading healthcare companies
Global Genetic Disorders Partnering 2010 t- 2016 provides the full collection of Genetic Disorders disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.
Trends in Genetic Disorders partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Genetic Disorders partnering agreement structure
Genetic Disorders partnering contract documents
Top Genetic Disorders deals by value
Most active Genetic Disorders dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right t- license a licensor’s product or technology. More often these days these deals tend t- be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.
The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers t- analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.
Chapter 1 provides an introduction t- the report.
Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Genetic Disorders deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals t- which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access t- the contract.
Chapter 5 provides comprehensive access t- Genetic Disorders deals since 2010 where a deal contract is available, providing the user with direct access t- contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink t- an online version of the deal record contract document, providing easy access t- each contract document on demand.
Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2010. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.
The report als- includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs t- know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.
Global Genetic Disorders Partnering 2010 t- 2016 is intended t- provide the reader with an in-depth understanding and access t- Genetic Disorders trends and structure of deals entered int- by leading companies worldwide.
Global Genetic Disorders Partnering 2010 t- 2016 includes:
Trends in Genetic Disorders dealmaking in the biopharma industry since 2010
Analysis of Genetic Disorders deal structure
Access t- headline, upfront, milestone and royalty data
Access t- hundreds of Genetic Disorders deal contract documents
Comprehensive access t- over 3500 Genetic Disorders deal records
The leading Genetic Disorders deals by value since 2010
Most active Genetic Disorders dealmakers since 2010
In Global Genetic Disorders Partnering 2010 t- 2016, available deals and contracts are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Specific therapy indication
Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.
The Global Genetic Disorders Partnering 2010-2016 report provides comprehensive access t- available deals and contract documents for over 400 genetic disorders deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement t- the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Wh- is responsible for commercialization?
Wh- is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes t- be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear t- differ from partner t- partner or deal type t- deal type?
Which jurisdiction does the company insist upon for agreement law?
Global Genetic Disorders Partnering 2010 t- 2016 provides the reader with the following key benefits:
In-depth understanding of Genetic Disorders deal trends since 2010
Access Genetic Disorders deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Genetic Disorders partner companies
Comprehensive access t- over 750 links t- actual Genetic Disorders deals entered int- by the world’s biopharma companies
Indepth review of Genetic Disorders deals entered int- by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Genetic Disorders opportunities
Uncover companies actively partnering Genetic Disorders opportunities